
Enliven Therapeutics Investor Relations Material
Latest events

Study Update
Enliven Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Enliven Therapeutics Inc
Access all reports
Enliven Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors for cancer treatment. The company aims to address both existing and emerging unmet needs in oncology with a precision approach designed to improve patient survival and overall well-being. Their development pipeline includes advanced candidates such as ELVN-001 and ELVN-002, which are being explored for their potential to offer enhanced selectivity, combinability, and safety in treatment protocols. The company is headquartered in Boulder, Colorado, and its shares are listed on the Nasdaq.
Key slides for Enliven Therapeutics Inc


Study Update
Enliven Therapeutics Inc


Study Update
Enliven Therapeutics Inc
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
ELVN
Country
🇺🇸 United States